Statins for treating Alzheimer's disease: Truly ineffective?

European Neurology

Volumn 73, Issue 5-6, 2015, Pages 360-366

  Liang, Ting ^a   Li, Rong ^a   Cheng, Oumei ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Alzheimer's disease assessment scale; Apolipoprotein E 4 allele; Beta amyloid; Low density lipoprotein cholesterol; Mini mental state examination; Randomized controlled trial; Statins

Indexed keywords

ATORVASTATIN; CHOLINESTERASE INHIBITOR; DONEPEZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMANTINE; PLACEBO; RIVASTIGMINE; SIMVASTATIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ACUTE HEPATITIS; ADVERSE OUTCOME; ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR DISEASE; DAILY LIFE ACTIVITY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FUNCTIONAL ASSESSMENT; HUMAN; KIDNEY FAILURE; MINI MENTAL STATE EXAMINATION; MYALGIA; NAUSEA; PRIORITY JOURNAL; RISK FACTOR; URINARY TRACT INFECTION; AGED; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84930246184     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000382128     Document Type: Article

References (38)

1. Ricciarelli R, Puzzo D, Bruno O, et al: A novel mechanism for cyclic adenosine monophosphate-mediated memory formation: role of amyloid beta. Ann Neurol 2014; 75: 602-607.
2. Puzzo D, Privitera L, et al: Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory. Ann Neurol 2011; 69: 819-830.
3. Puzzo D, Privitera L, et al: Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 2008; 28: 14537-14545.
4. Cummings JL: Alzheimer's disease. N Engl J Med 2004; 351: 56-67.
5. Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-766.
6. Barrett PJ, Song Y, Van Horn WD, Hustedt EJ, Schafer JM, et al: The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 2012; 336: 1168-1171.
7. Puglielli L, Tanzi RE, Kovacs DM: Alzheimer's disease: the cholesterol connection. Nat Neurosci 2003; 6: 345-351.
8. Roses AD: Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med 1996; 47: 387-400.
9. Notkola IL, Sulkava R, Pekkanen J, et al: Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998; 17: 14-20.
10. Carter DB, Dunn E, McKinley DD, et al: Human apolipoprotein E4 accelerates beta-amyloid deposition in APPsw transgenic mouse brain. Ann Neurol 2001; 50: 468-475.
11. Sparks DL, Scheff SW, Hunsaker JC 3rd, Liu H, Landers T, et al: Induction of Alzheimerlike beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 1994; 126: 88-94.
12. Refolo LM, et al: A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2001; 8: 890-899.
13. Fassbender K, Simons M, Bergmann C, et al: Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A 2001; 98: 5856-5861.
14. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA: Statins and the risk of dementia. Lancet 2000; 356: 1627-1631.
15. Sjögren M, Gustafsson K, Syversen S, et al: Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. Dement Geriatr Cogn Disord 2003; 16: 25-30.
16. Li J, Wang YJ, Zhang M, Xu ZQ, Gao CY, Fang CQ, Yan JC, Zhou HD: Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 2011; 76: 1485-1491.
17. Grundy SM, Cleeman JI, Merz CN, et al: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239.
18. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD: Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008; 71: 344-350.
19. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, et al: Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002; 137: 149-155.
20. Li G, Higdon R, Kukull W, et al: Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004; 63: 1624-1628.
21. Shepherd J, Blauw GJ, et al: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-1630.
22. Jadad AR, Moore RA, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
23. Simons M, Schwärzler F, Lütjohann D, et al: Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002; 52: 346-350.
24. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, et al: Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005; 62: 753-757.
25. Feldman HH, Doody RS, et al: Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010; 74: 956-964.
26. Sano M, Bell KL, Galasko D, et al: A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011; 77: 556-563.
27. Deslypere JP: Clinical implications of the biopharmaceutical properties of fluvastatin. Am J Cardiol 1994; 73: 12D-17D.
28. Simons M, Keller P, De Strooper B, et al: Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 1998; 95: 6460-6464.
29. Simons M, Keller P, Dichgans J, Schulz JB: Cholesterol and Alzheimer's disease: is there a link? Neurology 2001; 57: 1089-1093.
30. Zeng F, Wang YJ, et al: The correlation between vascular risk factors and Alzheimer's disease. Alzheimers Dement 2013; 9: 740.
31. McGuinness B, Craig D, Bullock R, Malouf R, Passmore P: Statins for the treatment of dementia. Cochrane Database Syst Rev 2014; 7:CD007514.
32. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A: Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980; 7: 486-488.
33. Hock C, Konietzko U, Streffer JR, et al: Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38: 547-554.
34. Deschaintre Y, Richard F, Leys D, Pasquier F: Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 2009; 73: 674-680.
35. Butchart J, Birch B, Bassily R, Wolfe L, Holmes C: Male sex hormones and systemic inflammation in Alzheimer disease. Alzheimer Dis Assoc Disord 2013; 27: 153-156.
36. Alegret M, Silvestre JS: Pleiotropic effects of statins and related pharmacological experimental approaches. Methods Find Exp Clin Pharmacol 2006; 28: 627-656.
37. Ricciarelli R, Canepa E, et al: Cholesterol and Alzheimer's disease: a still poorly understood correlation. IUBMB Life 2012; 64: 931-935.
38. Krstic D, Knuesel I: Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol 2013; 9: 25-34.